Literature DB >> 34207568

Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation.

Monika Englert-Golon1, Mirosław Andrusiewicz2, Aleksandra Żbikowska2, Małgorzata Chmielewska2, Stefan Sajdak1, Małgorzata Kotwicka2.   

Abstract

Ovarian cancer remains the leading cause of death due to gynecologic malignancy. Estrogen-related pathways genes, such as estrogen receptors (ESR1 and ESR2) and their coregulators, proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), and proto-oncogene tyrosine-protein kinase c-Src (SRC) are involved in ovarian cancer induction and development, still they require in-depth study. In our study, tissue samples were obtained from 52 females of Caucasian descent (control group without cancerous evidence (n = 27), including noncancerous benign changes (n = 15), and the ovarian carcinoma (n = 25)). Using quantitative analyses, we investigated ESRs, PELP1, and SRC mRNA expression association with ovarian tumorigenesis. Proteins' presence and their location were determined by Western blot and immunohistochemistry. Results showed that PELP1 and SRC expression levels were found to differ in tissues of different sample types. The expression patterns were complex and differed in the case of ovarian cancer patients compared to controls. The most robust protein immunoreactivity was observed for PELP1 and the weakest for ESR1. The expression patterns of analyzed genes represent a potentially interesting target in ovarian cancer biology, especially PELP1. This study suggests that specific estrogen-mediated functions in the ovary and ovary-derived cancer might result from different local interactions of estrogen with their receptors and coregulators.

Entities:  

Keywords:  estrogen receptors (ESR1 and ESR2); estrogen signal transduction coregulators; ovarian cancer; proline-, glutamic acid-, and leucine-rich protein 1 (PELP1); proto-oncogene tyrosine-protein kinase c-Src (SRC)

Year:  2021        PMID: 34207568     DOI: 10.3390/ijms22126216

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  6 in total

1.  Estrogen Receptor Type 1 and Type 2 Presence in Paravertebral Skeletal Muscles: Expression Level and Relation to Phenotype in Children with Idiopathic Scoliosis.

Authors:  Tomasz Kotwicki; Marek Tomaszewski; Mirosław Andrusiewicz; Aleksandra Śliwa; Błażej Rusin; Małgorzata Kotwicka
Journal:  Genes (Basel)       Date:  2022-04-22       Impact factor: 4.141

2.  Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas.

Authors:  Magdalena Spałkowska; Grzegorz Dyduch; Elżbieta Broniatowska; Giovanni Damiani; Anna Wojas-Pelc
Journal:  Medicina (Kaunas)       Date:  2021-11-11       Impact factor: 2.430

Review 3.  Estrogen Biosynthesis and Signal Transduction in Ovarian Disease.

Authors:  Xue-Ling Xu; Zheng-Yuan Huang; Kun Yu; Jun Li; Xiang-Wei Fu; Shou-Long Deng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

4.  Advances in Cancer Metabolism and Tumour Microenvironment.

Authors:  Karel Smetana; Michal Masařík
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 5.923

5.  Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia.

Authors:  Monika Englert-Golon; Małgorzata Tokłowicz; Aleksandra Żbikowska; Stefan Sajdak; Małgorzata Kotwicka; Mirosław Andrusiewicz
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

6.  Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer.

Authors:  Jianlin Zhu; Lu Wang; Fan Liu; Jinghua Pan; Zhimeng Yao; Yusheng Lin; Yabing Yang; Xiao Xiong; Kai Li; Yi Yang; Yiran Zhang; Xiaodong Chu; Yunlong Pan; Hao Zhang
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.